Information, not a decision

Acute lymphoblastic leukaemia: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 12 Nov 2026

Open trials (617)

NCT07572136	Phase 1	Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)	Recruiting
NCT07927816	Phase 1	CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	Recruiting
NCT07570173	Phase 2/3	A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)	Recruiting
NCT03263572	Phase 2	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	Recruiting
NCT06308588	Phase 1/2	Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Recruiting
NCT04877522	Phase 4	Asciminib Roll-over Study	Recruiting
NCT07388563	Phase 1	Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma	Recruiting
NCT07313852	Phase 1/2	A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia	Not yet recruiting
NCT07921550	No phase	Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL	Not yet recruiting
NCT07790913	Phase 2	Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma	Not yet recruiting
NCT07108868	Phase 1	A Phase I Dose Finding Study of MB-CART2219.1	Recruiting
NCT07923071	Phase 1	A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment	Not yet recruiting

605 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

No phase 3 trial in this list ended in the last 90 days.

Guidelines

ESMO Clinical Practice Guidelines
NCCN Guidelines
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.
[Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)].

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 12 Nov 2026

https://frontlightresearch.com/en/doctor/acute-lymphoblastic-leukemia/tumor-board